文献分享 | 利用MDCK悬浮细胞高效生产H9N2流感疫苗

Highly Efficient Production of an Influenza H9N2 Vaccine Using MDCK Suspension Cells
Yixiao Wu, Hanjing Jia, Xuping Liu,Wen-Song Tan. Highly Efficient Production of an Influenza H9N2 Vaccine Using MDCK Suspension Cells. Bioresources and Bioprocessing, 2020, 7: 63
Abstract: The use of H9N2 subtype avian influenza vaccines is an effective approach for the control of the virus spread among the poultry, and for the upgrading of vaccine manufacturing, cell culture-based production platform could overcome the limitations of conventional egg-based platform and alternate it. The development of serum-free suspension cell culture could allow even higher virus productivity, where a suspension cell line with good performance and proper culture strategies are required. In this work, an adherent Mardin–Darby canine kidney (MDCK) cell line was adapted to suspension growth to cell concentration up to 12× cells/mL in a serum-free medium in batch cultures. Subsequently, the H9N2 influenza virus propagation in this MDCK cell line was evaluated with the optimization of infection conditions in terms of MOI and cell concentration for infection. Furthermore, various feed strategies were tested in the infection phase for improved virus titer and a maximum hemagglutinin titer of 13
(HAU/50 μL) was obtained using the 1:2 medium dilution strategy. The evaluation of MDCK cell growth and H9N2 virus production in bioreactors with optimized operating conditions showed comparable cell performance and virus yield compared to shake flasks, with a high cell-specific virus yield above 13,000 virions/cell. With the purified H9N2 virus harvested from the bioreactors, the MDCK cell-derived vaccine was able to induce high titers of neutralizing antibodies in chickens. Overall, the results demonstrate the promising application of the highly efficient MDCK cell-based production platform for the avian influenza vaccine manufacturing.
利用MDCK悬浮细胞高效生产H9N2流感疫苗
摘 要:H9N2亚型禽流感疫苗的使用是控制禽流感病毒在禽类间传播的有效途径,而细胞培养生产平台能够克服传统鸡蛋平台的局限性并对其替代,从而实现疫苗生产工艺的升级。无血清悬浮细胞培养技术的发展,特别是高产悬浮细胞株的开发和培养策略的优化,能够有助于提高病毒的产量。本研究将一株贴壁型MDCK细胞系进行了无血清悬浮驯化,批培养条件下最高细胞密度可达12× cells/mL。随后对H9N2流感病毒在MDCK悬浮细胞系中的扩增情况进行了评估,并从MOI和感染时的细胞密度等方面对感染条件进行了优化。此外,为感染期提高病毒滴度,本研究考察了不同的补料策略,并发现采用1:2培养基稀释策略时能获得最大的HA滴度13
(HAU/50μL)。进一步对比经操作条件优化的生物反应器和摇瓶培养体系,MDCK细胞的性能和病毒产量相当,但在反应器中单位细胞的病毒产量更高,达到13000 virions/cell以上。最后,生物反应器中收获并经纯化后的H9N2病毒,也即MDCK细胞生产的疫苗能够在鸡体内诱导高滴度的中和抗体。综上,这些结果显示了MDCK细胞高效生产平台在禽流感疫苗生产应用中的广阔前景。
本文已收录于倍谙基《细胞培养工程精选论文集》Part II

倍谙基在动物细胞培养,尤其是基于反应器的大规模高密度培养有30多年的研发和项目经验,已有疫苗领域用到的细胞培养基全线产品。
